Immunogenicity and Safety of 13-valent Conjugated Pneumococcal Vaccine in Patients with Rheumatoid Arthritis
Relevance. Pneumococci are among the most common causative agents of severe bacterial infections in humans. The prevalence of invasive pneumococcal infections among people with autoimmune inflammatory rheumatic diseases is 3–4 times higher than in the general population. Aim. To evaluate the effecti...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Numikom LLC
2024-03-01
|
| Series: | Эпидемиология и вакцинопрофилактика |
| Subjects: | |
| Online Access: | https://www.epidemvac.ru/jour/article/view/1942 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849774983134314496 |
|---|---|
| author | B. T. Batozhargalova M. P. Kostinov A. D. Shmitko G. V. Lukina D. A. Murtazalieva E. N. Koltsova E. V. Zhilyaev |
| author_facet | B. T. Batozhargalova M. P. Kostinov A. D. Shmitko G. V. Lukina D. A. Murtazalieva E. N. Koltsova E. V. Zhilyaev |
| author_sort | B. T. Batozhargalova |
| collection | DOAJ |
| description | Relevance. Pneumococci are among the most common causative agents of severe bacterial infections in humans. The prevalence of invasive pneumococcal infections among people with autoimmune inflammatory rheumatic diseases is 3–4 times higher than in the general population. Aim. To evaluate the effectiveness of vaccination with 13-valent pneumococcal conjugate vaccine (PCV 13) in patients with rheumatoid arthritis (RA). Materials and Methods. The data of scientific publications PubMed, Web of Science, elibrary, the National Inpatient Database of the USA, the Moscow Unified Register of Arthritis, the V. A. Nasonova Research Institute of Rheumatology were used in the review. V. A. Nasonova Research Institute of Rheumatology. Conclusion. In the presented review in adult patients with rheumatoid arthritis (RA) receiving various antirheumatic drugs, the immunogenicity (humoral response, opsonophagocytic activity), safety of vaccines of 13-valent conjugated pneumococcal vaccine (PCV13) was assessed. Based on the data presented, a conclusion was made about the safe management of PCV13 and the formation of antibodies to pneumococcus in RA patients with targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs), biologic (bDMARDs) and Glucocorticoids (GCs < 15 mg daily). Methotrexate (MTX) in RA patients reduced the pneumococcal response and the functional activity of antibodies. |
| format | Article |
| id | doaj-art-032c0eec629c4b5f87d24d0ec21d57d4 |
| institution | DOAJ |
| issn | 2073-3046 2619-0494 |
| language | Russian |
| publishDate | 2024-03-01 |
| publisher | Numikom LLC |
| record_format | Article |
| series | Эпидемиология и вакцинопрофилактика |
| spelling | doaj-art-032c0eec629c4b5f87d24d0ec21d57d42025-08-20T03:01:34ZrusNumikom LLCЭпидемиология и вакцинопрофилактика2073-30462619-04942024-03-01231778810.31631/2073-3046-2024-23-1-77-881014Immunogenicity and Safety of 13-valent Conjugated Pneumococcal Vaccine in Patients with Rheumatoid ArthritisB. T. Batozhargalova0M. P. Kostinov1A. D. Shmitko2G. V. Lukina3D. A. Murtazalieva4E. N. Koltsova5E. V. Zhilyaev6Federal State Budgetary Scientific Institution «I.Mechnikov Research Institute of Vaccines and Sera»Federal State Budgetary Scientific Institution «I.Mechnikov Research Institute of Vaccines and Sera»; I.M. Sechenov First Moscow State Medical University (Sechenov University)Federal State Budgetary Scientific Institution «I.Mechnikov Research Institute of Vaccines and Sera»A.S. Loginov Moscow Clinical Scientific Center; V.A. Nasonova Research Institute of RheumatologyA.S. Loginov Moscow Clinical Scientific CenterA.S. Loginov Moscow Clinical Scientific CenterCJSC «European Medical Center»; Russian Medical Academy of Continuing Professional Education Ministry of Health of Russia; Russian National Research Medical University named after N.I. Pirogov" Ministry of Health of RussiaRelevance. Pneumococci are among the most common causative agents of severe bacterial infections in humans. The prevalence of invasive pneumococcal infections among people with autoimmune inflammatory rheumatic diseases is 3–4 times higher than in the general population. Aim. To evaluate the effectiveness of vaccination with 13-valent pneumococcal conjugate vaccine (PCV 13) in patients with rheumatoid arthritis (RA). Materials and Methods. The data of scientific publications PubMed, Web of Science, elibrary, the National Inpatient Database of the USA, the Moscow Unified Register of Arthritis, the V. A. Nasonova Research Institute of Rheumatology were used in the review. V. A. Nasonova Research Institute of Rheumatology. Conclusion. In the presented review in adult patients with rheumatoid arthritis (RA) receiving various antirheumatic drugs, the immunogenicity (humoral response, opsonophagocytic activity), safety of vaccines of 13-valent conjugated pneumococcal vaccine (PCV13) was assessed. Based on the data presented, a conclusion was made about the safe management of PCV13 and the formation of antibodies to pneumococcus in RA patients with targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs), biologic (bDMARDs) and Glucocorticoids (GCs < 15 mg daily). Methotrexate (MTX) in RA patients reduced the pneumococcal response and the functional activity of antibodies.https://www.epidemvac.ru/jour/article/view/1942pcv13vaccinationrheumatoid arthritisimmunogenicitysafety |
| spellingShingle | B. T. Batozhargalova M. P. Kostinov A. D. Shmitko G. V. Lukina D. A. Murtazalieva E. N. Koltsova E. V. Zhilyaev Immunogenicity and Safety of 13-valent Conjugated Pneumococcal Vaccine in Patients with Rheumatoid Arthritis Эпидемиология и вакцинопрофилактика pcv13 vaccination rheumatoid arthritis immunogenicity safety |
| title | Immunogenicity and Safety of 13-valent Conjugated Pneumococcal Vaccine in Patients with Rheumatoid Arthritis |
| title_full | Immunogenicity and Safety of 13-valent Conjugated Pneumococcal Vaccine in Patients with Rheumatoid Arthritis |
| title_fullStr | Immunogenicity and Safety of 13-valent Conjugated Pneumococcal Vaccine in Patients with Rheumatoid Arthritis |
| title_full_unstemmed | Immunogenicity and Safety of 13-valent Conjugated Pneumococcal Vaccine in Patients with Rheumatoid Arthritis |
| title_short | Immunogenicity and Safety of 13-valent Conjugated Pneumococcal Vaccine in Patients with Rheumatoid Arthritis |
| title_sort | immunogenicity and safety of 13 valent conjugated pneumococcal vaccine in patients with rheumatoid arthritis |
| topic | pcv13 vaccination rheumatoid arthritis immunogenicity safety |
| url | https://www.epidemvac.ru/jour/article/view/1942 |
| work_keys_str_mv | AT btbatozhargalova immunogenicityandsafetyof13valentconjugatedpneumococcalvaccineinpatientswithrheumatoidarthritis AT mpkostinov immunogenicityandsafetyof13valentconjugatedpneumococcalvaccineinpatientswithrheumatoidarthritis AT adshmitko immunogenicityandsafetyof13valentconjugatedpneumococcalvaccineinpatientswithrheumatoidarthritis AT gvlukina immunogenicityandsafetyof13valentconjugatedpneumococcalvaccineinpatientswithrheumatoidarthritis AT damurtazalieva immunogenicityandsafetyof13valentconjugatedpneumococcalvaccineinpatientswithrheumatoidarthritis AT enkoltsova immunogenicityandsafetyof13valentconjugatedpneumococcalvaccineinpatientswithrheumatoidarthritis AT evzhilyaev immunogenicityandsafetyof13valentconjugatedpneumococcalvaccineinpatientswithrheumatoidarthritis |